Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling

Retrospective observational studies have reported that statins improve clinical outcomes in patients previously treated with programmed cell death protein 1 (PD-1)-targeting monoclonal antibodies for malignant pleural mesothelioma (MPM) and advanced non-small cell lung cancer (NSCLC). In multiple mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Woo-Jin, Lee, Mingyu, Oh, Yerin, Fang, Xue-Quan, Lee, Sujin, Lim, Chang-Hoon, Park, Jooho, Lim, Ji-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472538/
https://www.ncbi.nlm.nih.gov/pubmed/34572136
http://dx.doi.org/10.3390/cells10092488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472538/
https://www.ncbi.nlm.nih.gov/pubmed/34572136
http://dx.doi.org/10.3390/cells10092488

Ejemplares similares